{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T03:34:39Z","timestamp":1776137679823,"version":"3.50.1"},"reference-count":10,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T00:00:00Z","timestamp":1103673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T00:00:00Z","timestamp":1103673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron Clin Pract"],"abstract":"<jats:p>&lt;i&gt;Background\/Aims:&lt;\/i&gt; Familial Mediterranean fever (FMF) is an autosomal recessive disease characterised by recurrent fever attacks and polyserositis which may lead to the development of AA amyloidosis and end-stage renal disease (ESRD). In this study, we aimed to evaluate the efficacy of continuous ambulatory peritoneal dialysis (CAPD) in FMF-amyloidosis patients with ESRD. &lt;i&gt;Methods:&lt;\/i&gt; Forty age- and sex-matched patients undergoing CAPD at our centre between 1996 and 2002 were included in the study. Of these, 10 had FMF-amyloidosis, 10 had diabetes mellitus (DM), 10 had chronic glomerulonephritis (CGN) and 10 had chronic interstitial nephritis (CIN). Efficiency of CAPD, development of complications, presence of other diseases and survival were compared. &lt;i&gt;Results:&lt;\/i&gt; With the onset of ESRD, the frequency of FMF peritonitis attacks decreased, with less attacks occurring during CAPD in FMF-amyloidosis patients (p &lt; 0.05). There was no significant difference between the FMF-amyloidosis group and other groups in terms of efficiency of CAPD, peritoneal function, complications and survival. DM patients had a shorter survival period compared with CGN and CIN patients (p &lt; 0.05), but there was no survival difference between FMF-amyloidosis patients and other groups (p &gt; 0.05). &lt;i&gt;Conclusions:&lt;\/i&gt; We conclude that CAPD is an effective and safe renal replacement therapy for FMF-amyloidosis patients with ESRD.<\/jats:p>","DOI":"10.1159\/000081553","type":"journal-article","created":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T21:06:35Z","timestamp":1103749595000},"page":"c119-c123","source":"Crossref","is-referenced-by-count":10,"title":["Continuous Ambulatory Peritoneal Dialysis in Familial Mediterranean Fever Amyloidosis Patients with End-Stage Renal Failure: A Single-Centre Experience from Turkey"],"prefix":"10.1159","volume":"98","author":[{"given":"Mehmet R\u0131za","family":"Alt\u0131parmak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6mer Nuri","family":"Pamuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rezzan","family":"Ataman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamil","family":"Serdenge\u00e7ti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2004,12,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016%2F0002-9343%2867%2990167-2"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM197410312911803"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM198604173141601"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2FS0022-3468%2880%2980014-5"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002%2Fart.1780401023"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1525-139X.1996.tb00689.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210%2Fjcem-63-5-1163"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001%2Farchinte.136.4.449"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136%2Fard.61.1.79"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002%2Fart.1780250106"}],"container-title":["Nephron Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/81553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/81553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:46:01Z","timestamp":1745466361000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000081553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,22]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2004,12,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000081553","archive":["Portico"],"relation":{},"ISSN":["1660-2110"],"issn-type":[{"value":"1660-2110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,22]]}}}